Source: Lancet diabetes & endocrinology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 17 ago. 2024.APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 ago. 17 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 ago. 17 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5